Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab and Lenalidomide in R/R Large B-cell Lymphoma Post CAR T-cell Therapy
NCT07814001Phase 2Not yet recruiting
- Sponsor
- LYSARC
- Start
- Dec 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Primary endpoint: Overall Response Rate at 56 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07814001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814001.